Trial Profile
A Phase II Study of Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary)
- Indications Haemangiosarcoma; Leiomyosarcoma; Liposarcoma; Malignant fibrous histiocytoma; Soft tissue sarcoma; Synovial sarcoma
- Focus Therapeutic Use
- 24 Jul 2020 Status changed from active, no longer recruiting to completed.
- 23 Jul 2020 Results published in the European Journal of Cancer
- 28 May 2020 Planned End Date changed from 30 Nov 2020 to 30 Nov 2021.